FDA Approves Degevma Biosimilar for Bone Complications and Tumors

The U.S. Food and Drug Administration (FDA) has approved Degevma (denosumab-adet), a biosimilar to Xgeva (denosumab). This approval covers all indications of its reference product, including preventing bone complications in adults with advanced cancer that has spread to the bone. It also treats adults and adolescents with giant cell tumor of bone, and hypercalcemia of malignancy.